

Amendments to the Claims:

This listing of claims will replace all prior versions of claims in the application:

Listing of Claims:

1-14. (Canceled)

15. (New) A therapeutic composition comprising IgY polyclonal antibodies and a physiologically acceptable carrier, excipient or diluent, wherein the IgY polyclonal antibodies specifically bind to one or more of gliadin, HMG and LMG in the gastrointestinal tract of a subject, and inhibit transport of gliadin, HMG and LMG into the mucosal membrane of the gastrointestinal tract of the subject.

16. (New) The composition of claim 15, wherein the IgY polyclonal antibodies are prepared by (a) immunizing an egg-laying fowl with one or more of gliadin, HMG, and LMG, (b) collecting eggs from the immunized fowl, (c) preparing the composition from the egg yolk or IgY purified from the egg yolk.

17. (New) The composition of claim 16 comprising an anti-gliadin antibody, an anti-HMG antibody, or an anti-LMG antibody, or mixtures thereof.

18. (New) The composition of claim 15, comprising egg yolk comprising anti-gluten antibodies.

19. (New) The composition of claim 18 wherein the egg yolk is liquid or dried, and formed into an oral dosage form.

20. (New) The composition of claim 15 which is a food product or beverage.

21. (New) In a therapeutic composition for treating or ameliorating the symptoms of celiac disease or a gluten sensitive condition, the improvement comprising a therapeutic agent comprising IgY anti-gluten antibodies which resist digestion with trypsin for up to four hours, and are stable at temperatures below about 75°C, specifically bind to one or more of gliadin, HMG and LMG in the gastrointestinal tract of a subject, and inhibit transport of gliadin, HMG and LMG into the mucosal membrane of the gastrointestinal tract of the subject.